1 completed, 1 no longer available, 1 suspended. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Suspended 1 |
Follow CA102N: new trials by email Literature Review of CA102N trials Research Report on CA102N
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors CA102N, LONSURF - Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC) | Phase 1 | Completed | Holy Stone Healthcare Co., Ltd | 37 | 2019-04-09 | 2022-09-21 |
| Individual Patient Expanded Access to CA102N CA102N - Advanced or Metastatic Colorectal Cancer (mCRC) | No longer available | Holy Stone Healthcare Co., Ltd | 2026-09-18 |
Holy Stone Healthcare Co., Ltd (3)
United States (2)
Shubham Pant, MD (1)